Meet our Management Team:
Ken Batchelor has more than 35 years of experience in drug discovery and development in the pharmaceutical and biotech industries, including 10 years as SVP for Drug Discovery with GSK in RTP, NC. Ken is co-inventor of the dual 5α-reductase inhibitor, Avodart, a blockbuster drug for the treatment of BPH.
He was responsible for the discovery and early development of drugs for the treatment of cancer (Tykerb (dual kinase inhibitor) and Votrient (VEGFTK inhibitor)), and type 2 diabetes (denagliptin (DPP4 inhibitor), remogliflozin (SGLT2 inhibitor), Tanzeum (long-acting GLP1 agonist) and farglitazar (PPARγ)).
As CEO of NovaTarg Therapeutics, Ken applies his flair for innovative drug discovery to the identification of new medicines for cancer and metabolic diseases.
Jeff Cobb, PhD (synthetic organic chemistry, University of South Carolina; postdoc: Oxford University) has 30 years of experience in drug discovery in metabolic diseases. He spent 13 years in medicinal chemistry groups at Sandoz, Glaxo, and GlaxoWellcome and an additional 8 years in the Metabolic Diseases biology group at GSK.
Jeff has focused on the early stages of drug discovery: target identification and validation, lead generation, and optimization. As Director, New Drugs for Metabolic Diseases, at GSK, he was responsible for the early nurturing of many projects, ultimately producing clinical candidates. Jeff is co-inventor of farglitazar (diabetes).
After leaving GSK, he has worked on novel diagnostics at Metabolon and as a freelance consultant in metabolic diseases, medicinal chemistry and pharmacology. Jeff is VP for Drug Discovery at NovaTarg Therapeutics.
Nick Livingston joined NovaTarg Therapeutics as Vice President of Biology in 2012 having spent 20 years in the pharmaceutical industry. Nick specializes in early drug discovery projects on a number of disease states, ranging from target conception to Phase ll clinical studies. Previously, he was Vice President at GlaxoSmithKline (GSK) in charge of biology for the Metabolic CEDD, the Center of Excellence in Drug Discovery for diabetes, obesity, and the diseases of aging.
Prior to joining GSK, Nick was Vice President of Metabolic Diseases at Bayer Pharmaceuticals, where he was responsible for developing and managing the early discovery programs for type 2 diabetes and obesity.
Over his 20 years experience in the pharmaceutical industry, Nick has participated in numerous IND applications at Bayer and GSK, writing the preclinical pharmacology sections and reviewing the safety and DMPK sections for products in diabetes, obesity, and the diseases of aging, plus the successful NDA submission for the anti-diabetic drug, Miglitol.
Before joining the pharmaceutical industry, Dr. Livingston had a successful career in academic medicine at the University of Rochester Medical School, attaining the ranks of Professor of Medicine, Professor of Pediatrics, and Professor of Biochemistry. He has held academic appointments at Yale University School of Medicine and at the Johns Hopkins School of Medicine. Nick is the author or co-author of over 90 full-length articles on topics in metabolic diseases.